Anika Therapeutics, Inc. Proceeds from Sale of Notes Receivable
Anika Therapeutics, Inc. (ANIK) reported Proceeds from Sale of Notes Receivable of $361.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfNotesReceivable · last filed 2026-07-29
- Anika Therapeutics, Inc. proceeds from sale of notes receivable for the quarter ending 2026-06-30 was $169.00K, a 48.48% decline year-over-year.
- Anika Therapeutics, Inc. proceeds from sale of notes receivable for the quarter ending 2026-03-31 was $192.00K.
- Anika Therapeutics, Inc. proceeds from sale of notes receivable for the quarter ending 2025-12-31 was $846.00K.
- Anika Therapeutics, Inc. proceeds from sale of notes receivable for the quarter ending 2025-09-30 was $155.00K.
- Anika Therapeutics, Inc. proceeds from sale of notes receivable for fiscal 2025 was $1.33M.
- Anika Therapeutics, Inc. proceeds from sale of notes receivable for fiscal 2024 was $0.00.
- Anika Therapeutics, Inc. proceeds from sale of notes receivable for fiscal 2023 was $0.00.
| Period end | Proceeds from Sale of Notes Receivable 3 month | Proceeds from Sale of Notes Receivable 6 month | Proceeds from Sale of Notes Receivable 9 month | Proceeds from Sale of Notes Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $169.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $361.00K 10-Q · filed 2026-07-29 | $1.21M derived: sum of 3 quarters · filed 2026-07-29 | $1.36M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $192.00K 10-Q · filed 2026-04-30 | $1.04M derived: sum of 2 quarters · filed 2026-04-30 | $1.19M derived: sum of 3 quarters · filed 2026-04-30 | $1.52M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $846.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.00M derived: sum of 2 quarters · filed 2026-03-03 | $1.33M derived: sum of 3 quarters · filed 2026-07-29 | $1.33M 10-K · filed 2026-03-03 |
| 2025-09-30 | $155.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $483.00K derived: sum of 2 quarters · filed 2026-07-29 | $483.00K 10-Q · filed 2025-11-05 | $483.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $328.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $328.00K 10-Q · filed 2026-07-29 | $328.00K derived: sum of 3 quarters · filed 2026-07-29 | $328.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | $0.00 derived: sum of 2 quarters · filed 2026-04-30 | $0.00 derived: sum of 3 quarters · filed 2026-04-30 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-07-30 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |